Baird cuts Dyne Therapeutics price target to $26 from $30
Baird cut its Dyne Therapeutics price target to $26.00 per share from $30.00, per Benzinga ratings actions.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.